Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

Francis J. Giles, Julie M. Vose, Kim Anh Do, Marcella M. Johnson, Taghi Manshouri, Gregory Bociek, Philip J. Bierman, Susan M. O'Brien, Hagop M. Kantarjian, James O. Armitage, Maher Albitar

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD.

Original languageEnglish (US)
Pages (from-to)595-604
Number of pages10
JournalLeukemia Research
Volume28
Issue number6
DOIs
StatePublished - Jun 2004

Keywords

  • Angiogenin
  • HGF
  • Hodgkin's
  • Lymphoma
  • Prognosis
  • Survival
  • VEGF
  • bFGF

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this